Literature DB >> 15917104

Sparing of age-related macular degeneration in rheumatoid arthritis.

Patrick L McGeer1, John Sibley.   

Abstract

Age-related macular degeneration (AMD), for which inflammatory changes have been demonstrated, is the commonest cause of blindness in the elderly. We compared the prevalence of AMD in a prospectively followed cohort of rheumatoid arthritic (RA) patients from Saskatchewan with published data from four racially similar general populations. For individuals 65 years or older, only three cases of AMD were identified in the Saskatchewan cohort of 993 RA patients (0.2% prevalence). This compares with 67 out of 1955 subjects in the Beaver Dam survey (prevalence 3.43%); 101 out of 4071 in the Rotterdam survey (prevalence 2.48%); and 63 out of 1950 in the Blue Mountains survey (prevalence 3.23%). For individuals 75 years or older, only two cases out of 497 were identified in the RA cohort (prevalence 0.40%), compared with 516 cases out of 13,900 in the United Kingdom survey (prevalence 3.72%). Patients with RA appear to be relatively spared from AMD. We hypothesize that this results from long term antiinflammatory treatment. Genetic or environmental factors could also be responsible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917104     DOI: 10.1016/j.neurobiolaging.2005.02.003

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  14 in total

1.  The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment.

Authors:  Y Wang; V M Wang; C-C Chan
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

2.  Intravitreal injection of (99)Tc-MDP inhibits the development of laser-induced choroidal neovascularization in rhesus monkeys.

Authors:  Kunbei Lai; Chenjin Jin; Shu Tu; Yunfan Xiong; Rui Huang; Jian Ge
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-05       Impact factor: 3.117

3.  Age-related macular degeneration in patients with uveitis.

Authors:  Austin R Fox; Emily Y Chew; Catherine Meyerle; Susan Vitale; Frederick L Ferris; Robert B Nussenblatt; H Nida Sen
Journal:  Br J Ophthalmol       Date:  2016-05-06       Impact factor: 4.638

4.  A retrospective evaluation of the effect of hydroxyquinine on RPE thickness.

Authors:  Joseph Pikkel; Otzem Chassid; Adi Sharabi-Nov; Itchak Beiran
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-01-16       Impact factor: 3.117

5.  Progress and perspectives on the role of RPE cell inflammatory responses in the development of age-related macular degeneration.

Authors:  Suofu Qin; Gerard A Rodrigues
Journal:  J Inflamm Res       Date:  2008-12-02

6.  Chronic, Systemic Interleukin-18 Does Not Promote Macular Degeneration or Choroidal Neovascularization.

Authors:  Scott W Canna; Guangpu Shi; Igal Gery; H Nida Sen
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-03-01       Impact factor: 4.799

Review 7.  Parainflammation, chronic inflammation, and age-related macular degeneration.

Authors:  Mei Chen; Heping Xu
Journal:  J Leukoc Biol       Date:  2015-08-20       Impact factor: 4.962

8.  Nonsteroidal anti-inflammatory drugs for retinal disease.

Authors:  Scott D Schoenberger; Stephen J Kim
Journal:  Int J Inflam       Date:  2013-01-14

Review 9.  Topical nonsteroidal anti-inflammatory drugs for macular edema.

Authors:  Andrea Russo; Ciro Costagliola; Luisa Delcassi; Francesco Parmeggiani; Mario R Romano; Roberto Dell'Omo; Francesco Semeraro
Journal:  Mediators Inflamm       Date:  2013-10-21       Impact factor: 4.711

10.  Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study.

Authors:  Dorota Wyględowska-Promieńska; Anna Piotrowska-Gwóźdź; Agnieszka Piotrowska-Seweryn; Grażyna Mazur-Piotrowska; Wojciech Rokicki
Journal:  Med Sci Monit       Date:  2014-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.